Back to News
Market Impact: 0.2
ResMed Targets 12%-14% EPS Growth as GLP-1 Patients Lift Sleep Therapy Demand
Source: marketbeat.com
Healthcare & BiotechCorporate Guidance & OutlookCompany FundamentalsProduct Launches
ResMed outlined its growth, margin and portfolio strategy at a Morgan Stanley discussion, emphasizing demand generation, patient adherence and continued innovation in sleep and respiratory care. The update signals a constructive operational outlook but provided no new financial targets, earnings figures or material product details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.18
Ticker Sentiment
MS0.05
RMD0.42
More News
- Glanbia shares tumble 6% after Morgan Stanley cuts rating to underweight
- The latest twist in the saga between UBS and Swiss regulators involves bank's New York business
- Morgan Stanley downgrades Ebara stock rating on valuation concerns
- AI debt concerns grow as ING reportedly seeks buyers for $500 million of data center loans
- Tech stock rout, driven by US AI fears, continues in Asian trading
- Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction